It does not guarantee cosmetic outcomes, and it does not replace medical care
In patients with HFpEF and obesity, both semaglutide (STEP-HFpEF) and tirzepatide (SUMMIT) significantly reduced cardiovascular death and worsening heart failure events, with concomitant improvements in quality of life and functional capacity [3,47]
A healthier liver function can improve metabolism and may even support weight management indirectly
When evaluated with more sensitive and reliable 24-h continuous monitoring and in thorough QT studies, two of the long-acting GLP-1 RAs, liraglutide and albiglutide, were shown to cause a pronounced increase in the 24-h time-averaged mean HR from baseline of up to 610 bpm, while for dulaglutide and exenatide LAR, the increase in 24-h mean HR was 34 bpm [23, 24, 27,28,29,30]